Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Large B-Cell, Diffuse

Explore clinical trials studying Lymphoma, Large B-Cell, Diffuse. Study availability and eligibility vary by location and protocol.

1,257 public trials 216 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Large B-Cell, Diffuse trial results

Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +37 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
View all 115 locations
View Trial Details
Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Conditions
DLBCL, Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, +10 more
Locations
  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175) Glendale, Arizona, United States
  • Beverly Hills Cancer Center ( Site 0184) Beverly Hills, California, United States
  • Bass Medical Group ( Site 0166) Walnut Creek, California, United States
  • Innovative Clinical Research Institute ( Site 0122) Whittier, California, United States
View all 135 locations
View Trial Details
Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Colorado Blood Cancer Institute ( Site 7000) Denver, Colorado, United States
  • SCRI Oncology Partners ( Site 0100) Nashville, Tennessee, United States
  • Instituto Alexander Fleming ( Site 1404) Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • Sanatorio Nuestra Senora del Rosario ( Site 1403) Rosario, Santa Fe Province, Argentina
View all 34 locations
View Trial Details
Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • USA Mitchell Cancer Institute ( Site 0173) Mobile, Alabama, United States
  • Banner MD Anderson Cancer Center ( Site 0165) Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) Phoenix, Arizona, United States
  • The University of Arizona Cancer Center - North Campus ( Site 0124) Tucson, Arizona, United States
View all 268 locations
View Trial Details
Recruiting

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT06806033

Conditions
B-Cell Non-Hodgkins Lymphoma, Cytokine Release Syndrome, Disease Attributes, +17 more
Locations
  • Alaska Oncology & Hematology, LLC Anchorage, Alaska, United States
  • Community Cancer Institute (CCI) Clovis, California, United States
  • Providence Medical Foundation Fullerton, California, United States
  • Los Angeles Cancer Network Glendale, California, United States
View all 53 locations
View Trial Details

Related conditions